Trials / Completed
CompletedNCT05123001
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 11 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to monitor physiological and molecular changes during and following CAR-T cancer cell therapy, towards improved management of adverse events including Cytokine Release Syndrome and neurotoxicity. Our study aims are to improved early detection and precise management of adverse events for patients receiving Chimeric antigen receptor T- cell (CAR-T): 1. To assess the feasibility, including accuracy, usability, and usefulness of wearable sensors in CAR-T patients. 2. To generate comprehensive multiomic profile analysis following CAR-T therapy. 3. To perform integrated analysis of wearables sensor data, omics data, and symptom/clinical data.
Conditions
Timeline
- Start date
- 2021-07-15
- Primary completion
- 2022-07-07
- Completion
- 2022-07-07
- First posted
- 2021-11-17
- Last updated
- 2025-08-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05123001. Inclusion in this directory is not an endorsement.